We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Laura Elizabeth Lansdowne

Managing Editor

Contact Us

Writes for:

Drug Discovery Cancer Research

Latest Content From Laura Elizabeth Lansdowne

Stay Up-to-Date With COVID-19 Drug Development
Article

Researchers are working tirelessly to design new drugs and repurpose existing drugs against the novel coronavirus SARS-CoV-2.

VIEW

Exploiting the Therapeutic Potential of Plants
Industry Insight

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.

VIEW

180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases
Industry Insight

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

VIEW

Becoming a Science Writer
Video

"How do I become a science writer?" is a common question that we get asked here at Technology Networks. That is why for this installment of Teach Me in 10, the guests are … well, us! We wanted to share stories of how we became science writers and communicators, highlighting some of the things that we have learned through our journeys and offering some top tips and tricks.

VIEW

Cytisinicline: A Treatment To Help People Battling Nicotine Addiction
Industry Insight

The pharmaceutical company Achieve Life Sciences is focused on addressing one of the biggest public health threats globally – tobacco use. Technology Networks had the pleasure of speaking with the company's chief medical officer Cindy Jacobs, MD, PhD, to learn more about cytisinicline, a plant-based alkaloid the company is currently developing as a smoking cessation treatment.

VIEW

Behind the World-First Export of Jamaican Psilocybin Mushrooms
Industry Insight

Mydecine Innovations Group recently announced that it had completed the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. We spoke with Mydecine’s chief scientific officer and co-founder, Rob Roscow, to find out more.

VIEW

New Test Enables Non-Invasive Detection of Endometrial Cancer
Industry Insight

Arquer Diagnostics is developing non-invasive tests for diagnosing and monitoring cancer, using patented technology to detect the cancer biomarker MCM5. Technology Networks had the pleasure of speaking with Nadia Whittley, Chief Executive Officer of Arquer Diagnostics, to learn more about the study and its significance.

VIEW

Antibody–Drug Conjugate Reduces Risk of Death by 30% in Patients With Common Bladder Cancer
News

The antibody–drug conjugate (ADC) enfortumab vedotin (PADCEV®) has been shown to increase the survival of patients with urothelial carcinoma in a recent study. Results from the randomized open-label Phase 3 trial were published in the New England Journal of Medicine.

VIEW

Opinionated Science Episode 21: The Roundup – Moon Phases, Anti-Cancer Elephants and Poop Infusions
Podcast

In this episode, the TN team rounds up some of the best and weirdest science from the last month. Hear how elephants and naked mole rats fight cancer, how immunotherapy is getting a microbial boost from poop transplants and why researchers think our sleep patterns might be affected by the phases of the moon.

VIEW

Leveraging AI To Identify and Target Novel Cell–Cell Interactions
Industry Insight

Technology Networks recently had the pleasure of speaking with Sam Cooper, CEO and co-founder of Phenomic AI. Cooper discusses how the company is leveraging advanced machine learning techniques to interrogate cell–cell interactions responsible for driving many disease mechanisms.

VIEW